S&T BIOMED CO., LTD.
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
At the current stage, the primary focus is on developing oral cancer biomarker in vitro diagnostic reagent products, while also successively developing related precision screening technologies and products for major diseases such as pancreatic cancer and COVID-19. Striving towards product realization, the ultimate goal is to achieve "preventive medicine" and precision medicine.
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2016
Unified Business No.
66387476
Status
Active
Number of Employees
0
Total Paid-in
Capital
134,392,600 (NT$)
Location of Company
Taiwan
, Hsinchu County
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
In December 2016, S&T BIOMED CO., LTD. was established by three founders, including Chairman Hung-Ta Chiu. S&T BIOMED CO., LTD. is a technology-oriented company that continuously accumulates capabilities by integrating the technologies of top medical and industrial teams throughout Taiwan through industry-academia technology transfers. S&T BIOMED CO., LTD. has always adhered to the mission of providing simple, rapid, and accurate testing for cancer and performing effective disease management through its non-invasive biomarker detection service platform. Currently, the products launched on the market for clinical application are two "oral cancer in vitro diagnostic reagent" products, and commercial development is successively underway for major cancers such as pancreatic cancer, colorectal cancer, gastric cancer, and biliary tract cancer. The company hopes to provide simple, rapid, and accurate testing for cancer and achieve effective disease management through its non-invasive biomarker detection service platform, thereby striving for the greatest well-being of the health of our nation's people and humanity worldwide.
(The content above was translated by AI.)
(The content above was translated by AI.)
